OTCMKTS:AXIM

AXIM Biotechnologies Stock Forecast, Price & News

$0.58

-0.05 (-7.94 %)

(As of 03/5/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.51

Now: $0.58▼

$0.68

50-Day Range

$0.41

MA: $0.61▼

$0.86

52-Week Range

$0.10

Now: $0.58▼

$1.44

Volume175,850 shs

Average Volume397,234 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

AXIM Biotechnologies, Inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company's NeuCovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. It is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was founded in 2010 and is headquartered in San Diego, California.

Headlines

AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients
February 3, 2021 | finance.yahoo.com

AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies
January 11, 2021 | finance.yahoo.com

Axim Biotechnologies Inc
December 17, 2020 | bloomberg.com

AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies
December 15, 2020 | finance.yahoo.com

AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14
December 14, 2020 | finance.yahoo.com

AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application
December 3, 2020 | finance.yahoo.com

AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
November 10, 2020 | finance.yahoo.com

AXIM files patent for virus binding recombinant protein for SARS-CoV-2
September 30, 2020 | seekingalpha.com

AXIM® Biotechnologies Files Patent for World's First Face Mask Designed to Capture SARS-CoV-2 COVID-19
September 29, 2020 | benzinga.com

AXIM(R) Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
September 26, 2020 | marketwatch.com

AXIM Bio nabs additional US patent for anti-neoplastic compounds
September 22, 2020 | seekingalpha.com

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
September 22, 2020 | finance.yahoo.com

AXIM Bio seeks emergency use of COVID-19 rapid diagnostic test
September 16, 2020 | seekingalpha.com

Axim Bio inks manufacturing deal for COVID-19 antibody test
August 24, 2020 | seekingalpha.com

AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
August 24, 2020 | finance.yahoo.com

Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by
August 13, 2020 | bloomberg.com

Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute
August 11, 2020 | finance.yahoo.com

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Unveils World’s First COVID-19 Rapid Diagnostic Test for
August 8, 2020 | bloomberg.com

AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19
August 5, 2020 | finance.yahoo.com

AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine to Treat or
July 23, 2020 | www.bloomberg.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:AXIM

Previous Symbol

CUSIPN/A

CIK1514946

Webaximbiotech.com

Phone212-751-0001

Employees4

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.42 out of 5 stars

Medical Sector

1685th out of 1,969 stocks

Biotechnology Industry

92nd out of 125 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for AXIM Biotechnologies.

2.1 Community Rank

Outperform Votes
AXIM Biotechnologies has received 21 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AXIM Biotechnologies has received 28 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AXIM Biotechnologies has received 57.14% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AXIM Biotechnologies and other stocks. Vote “Outperform” if you believe AXIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXIM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AXIM Biotechnologies does not currently pay a dividend.
Dividend Growth
AXIM Biotechnologies does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AXIM Biotechnologies insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$0.58

-0.05 (-7.94 %)

(As of 03/5/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive AXIM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXIM and its competitors with MarketBeat's FREE daily newsletter.

AXIM Biotechnologies (OTCMKTS:AXIM) Frequently Asked Questions

What stocks does MarketBeat like better than AXIM Biotechnologies?

Wall Street analysts have given AXIM Biotechnologies a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AXIM Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AXIM Biotechnologies?

AXIM Biotechnologies saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 58,000 shares, an increase of 195.9% from the January 14th total of 19,600 shares. Based on an average trading volume of 443,400 shares, the short-interest ratio is currently 0.1 days.
View AXIM Biotechnologies' Short Interest.

How has AXIM Biotechnologies' stock been impacted by Coronavirus (COVID-19)?

AXIM Biotechnologies' stock was trading at $0.1781 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AXIM stock has increased by 225.6% and is now trading at $0.5799.
View which stocks have been most impacted by COVID-19.

Who are AXIM Biotechnologies' key executives?

AXIM Biotechnologies' management team includes the following people:

Mr. John W. Huemoeller II, Pres, CEO & Director (Age 66, Pay $210k)
Mr. Robert T. Malasek, CFO & Sec. (Age 53, Pay $30k)
Dr. Sergei A. Svarovsky Ph.D., Chief Scientific Officer & Co-Founder of Sapphire Biotech
Dr. Douglas Lake Ph.D., Chief Clinical Officer of Sapphire Biotech
Dr. Alim Seit-Nebi Ph.D., CTO & Co-Founder of Sapphire Biotech
Ms. Catalina Valencia J.D., Chief Exec. Officer of Sapphire Biotech

Who are some of AXIM Biotechnologies' key competitors?

Some companies that are related to AXIM Biotechnologies include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of AXIM's competitors.

What other stocks do shareholders of AXIM Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AXIM Biotechnologies investors own include (CGC), Cronos Group (CRON), (APHA), Tilray (TLRY), KushCo (KSHB), Aurora Cannabis (ACB), Curaleaf (CURLF), Charlotte's Web (CWBHF), Fulcrum Therapeutics (FULC) and Alibaba Group (BABA).

What is AXIM Biotechnologies' stock symbol?

AXIM Biotechnologies trades on the OTCMKTS under the ticker symbol "AXIM."

How do I buy shares of AXIM Biotechnologies?

Shares of AXIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AXIM Biotechnologies' stock price today?

One share of AXIM stock can currently be purchased for approximately $0.58.

How many employees does AXIM Biotechnologies have?

AXIM Biotechnologies employs 4 workers across the globe.

What is AXIM Biotechnologies' official website?

The official website for AXIM Biotechnologies is aximbiotech.com.

How can I contact AXIM Biotechnologies?

The company can be reached via phone at 212-751-0001.

This page was last updated on 3/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here